Four Companies Involved In The Diagnosis, Treatment, And Prevention Of Cte – Yahoo Finance

Since there is no current diagnosis tool available for CTE, if Exosome can get its candidate approved, it would be the only player in a large market of retired athletes. Going forward, this could bode well for Aethlon, making the latter an intriguing exposure especially given that a pivotal phase 2 trial is already completed. Amarantus Bioscience Holdings Sticking with diagnostics, and also with Boston University, Amarantus Bioscience Holdings, Inc ( AMBS ) is also trying its luck. At the beginning of last year, the company announced the inking of a collaboration with BU to investigate the efficacy of Amarantus’s LymPro dagnostic candidate as a CTE diagnosis tool. The CTE indication is an extension of its primary Alzheimer’s indication. It measures the ability of lymphocytes to withstand external stimulation, but the outcome of this measurement can not determine the severity of a neurodegenerative disease. The CTE indication is still in the very early stage for Amarantus, but if it can get the FDA to approve the Alzheimer’s diagnostic indication which is farther advanced, it could be hot on the heels of Aethlon in getting this tool to market. Medical Marijuana, Inc. Moving on to treatment – Medical Marijuana, Inc. ( MJNA ).

To read more visit

Share This Post

Recent Articles

Leave a Reply

© 2019 Medical Marijuana Stocks. All rights reserved. Site Admin · Entries RSS · Comments RSS
Powered by WordPress · Designed by Theme Junkie
Subscribe now!
Get the latest content first.
©Medical Marijuana